[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560496":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":39,"centralContacts":43,"locations":48,"responsibleParty":63,"collaborators":10,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":10,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":79,"studyType":80,"phases":10,"briefSummary":81,"conditions":82,"keywords":10,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Pusan National University Yangsan Hospital","OTHER",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Aged 75 or more",null,"Elderly patients aged 75 years or older",[13],"Device: Onyx family",{"label":15,"type":10,"description":16,"interventionNames":17},"Eligible for interventional procedures","\"Patients requiring PCI (Percutaneous Coronary Intervention) procedure",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Evidence of myocardial ischemia or coronary artery stenosis ≥ 50%","Patients with evidence of myocardial ischemia or coronary artery stenosis ≥ 50% on coronary angiography",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Able to take antiplatelets for at least 1 months after the procedure","Patients able to take antiplatelets after the procedure",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Patients who underwent coronary artery procedures with ZES stent","Patients who underwent coronary artery procedures with Onyx™ family stent",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DEVICE","Onyx family","Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents",[23,9,15,19,27],[37,38],"Onyx frontier","Resolute Onyx",[40],{"name":41,"affiliation":5,"role":42},"Min Ku Chon, MD,PhD","PRINCIPAL_INVESTIGATOR",[44],{"name":41,"role":45,"phone":46,"phoneExt":10,"email":47},"CONTACT","82-10-2562-6258","chonmingu@gmail.com",[49],{"facility":5,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":10,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Yangsan","Gyeongsangnam-do","50611","South Korea",{"type":56,"coordinates":57},"Point",[58,59],129.03358,35.34199,{"lat":59,"lon":58},[62],{"name":41,"role":45,"phone":46,"phoneExt":10,"email":47},{"type":42,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Min Ku Chon","Associate Professor","100560496","the-study-to-evaluate-the-safety-and-efficacy-of-the-onyx-family-100560496",false,"NCT06577896","The Study to Evaluate the Safety and Efficacy of the Onyx Family","Safety and Efficacy of 1-month Dual Antiplatelet Therapy in High Bleeding and Ischemic Risk Elderly Patients With Coronary Artery Disease After Implantation of Zotarolimus-eluting Coronary Stent System (Onyx Family, Medtronic, Minneapolis, MN); A Multicenter, Prospective, Observational Study","Inclusion Criteria:\n\n* Aged 75 or more.\n* Eligible for interventional procedures.\n* Evidence of myocardial ischemia or coronary artery stenosis ≥ 50%.\n* Able to take antiplatelets for at least 1 months after the procedure.\n* Patients who underwent coronary artery procedures with ZES (Medtronic, Minneapolis, MN, Onyx™ family) stent.\n\nExclusion Criteria:\n\n* The patient has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, zotarolimus, and contrast media (patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine \\[eg, rash\\] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled).\n* Patients with active pathologic bleeding.\n* Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.\n* History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia).\n* Noncardiac comorbid conditions are present with life expectancy \\<1 year or that may result in protocol noncompliance (per site investigator\\'s medical judgment).\n* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.","ALL","75 Years","100 Years",{"count":77,"type":78},500,"ESTIMATED","1 Year","OBSERVATIONAL","Observation of the safety and efficacy of 1-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention using Onyx family stents in elderly patients aged 75 years or older",[83],"Coronary Artery Disease","2024-09-05",{"date":86,"type":87},"2024-09-19","ACTUAL",{"date":89,"type":87},"2022-06-09",{"date":91,"type":78},"2026-12-31",{"name":5,"class":6},1]